Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT D FISHBERG

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1871587345
CMS profile
176292
Location
SPRINGFIELD, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$26,603.43

149 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT D FISHBERG

NPI 1871587345 · CMS profile ID 176292

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SPRINGFIELD, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT D FISHBERG, NPI 1871587345, CMS profile ID 176292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ROBERT D FISHBERG, NPI 1871587345, CMS profile ID 176292. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ROBERT D FISHBERG, NPI 1871587345, CMS profile ID 176292, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1871587345?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

149 matching records · $26,603.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 149 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–149 of 149.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $4.4605/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208144 CMS
Alnylam Pharmaceuticals Inc. $18.6605/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212788400 CMS
Merck Sharp & Dohme LLC $16.3204/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238375312 CMS
Lilly USA, LLC $15.8604/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186901202 CMS
Amgen Inc. $13.9204/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227230156 CMS
Amgen Inc. $125.0004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228540213 CMS
E.R. Squibb & Sons, L.L.C. $3.8804/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801241 CMS
E.R. Squibb & Sons, L.L.C. $6.7104/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801231 CMS
Boston Scientific Corporation $34.3404/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181419036 CMS
Novartis Pharmaceuticals Corporation $13.6104/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208140 CMS
Esperion Therapeutics, Inc. $14.6204/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243958388 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.5904/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225537041 CMS
Regeneron Pharmaceuticals, Inc. $41.2504/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213237805 CMS
Merck Sharp & Dohme LLC $15.4804/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238157553 CMS
Novartis Pharmaceuticals Corporation $4.5404/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208142 CMS
Novo Nordisk Inc $18.8704/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188223595 CMS
Amgen Inc. $19.1904/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228540211 CMS
Baxter Healthcare $37.1803/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181559894 CMS
Novartis Pharmaceuticals Corporation $18.1103/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208138 CMS
Edwards Lifesciences Corporation $150.3103/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225244865 CMS
E.R. Squibb & Sons, L.L.C. $13.6203/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801217 CMS
Regeneron Healthcare Solutions, Inc. $18.1003/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212920104 CMS
Novartis Pharmaceuticals Corporation $4.7103/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208132 CMS
Novartis Pharmaceuticals Corporation $1.3403/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208134 CMS
PFIZER INC. $17.0003/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231404835 CMS
Amgen Inc. $103.9002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228540215 CMS
E.R. Squibb & Sons, L.L.C. $5.8502/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801205 CMS
Regeneron Healthcare Solutions, Inc. $18.9002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212920102 CMS
ENDOTRONIX, INC. $31.0802/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1239001912 CMS
E.R. Squibb & Sons, L.L.C. $13.8302/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801209 CMS
PFIZER INC. $16.0602/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231376318 CMS
Regeneron Healthcare Solutions, Inc. $732.7502/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1212920098 CMS
Regeneron Healthcare Solutions, Inc. $3,908.0002/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1212920100 CMS
Amgen Inc. $2,800.0002/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226889101 CMS
Amgen Inc. $5.5402/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227230142 CMS
Amgen Inc. $89.3802/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228540223 CMS
Lilly USA, LLC $16.5302/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186881111 CMS
Chiesi USA, Inc. $21.8802/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242159253 CMS
E.R. Squibb & Sons, L.L.C. $17.1302/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801189 CMS
Novartis Pharmaceuticals Corporation $15.6902/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208136 CMS
Novo Nordisk Inc $18.7802/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188545452 CMS
Amgen Inc. $13.9202/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227230148 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.0201/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225537039 CMS
Merck Sharp & Dohme LLC $18.2501/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238064804 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.7201/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223067049 CMS
AstraZeneca Pharmaceuticals LP $16.9701/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206276024 CMS
Novo Nordisk Inc $18.9601/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188736577 CMS
E.R. Squibb & Sons, L.L.C. $1.4701/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801175 CMS
E.R. Squibb & Sons, L.L.C. $10.7801/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184801177 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,824.43 66
PY2020 $8,777.01 41
PY2021 $12,513.04 46
PY2022 $7,506.13 74
PY2023 $13,772.27 89
PY2024 $10,528.86 112
PY2025 $26,603.43 149

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $804,076.31 19
PY2024 Recipient $33,559.00 1
PY2024 Principal investigator $292,861.28 14
PY2023 Principal investigator $249,132.65 7
PY2022 Principal investigator $238,922.01 4
PY2021 Principal investigator $167,569.21 11
PY2020 Principal investigator $40,813.46 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,493.48 12/16/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190297238
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,744.00 11/24/2025 Non-covered Recipient Entity
ATLANTIC HEALTH SYSTEM DBA ATLANTIC CORPORATE HEALTH DEPARTMENT OF ATLANTIC CORPORATE HEALTH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190309416
Principal investigator 1 Novartis Pharmaceuticals Corporation $286.56 10/27/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190297235
Principal investigator 1 Novartis Pharmaceuticals Corporation $935.54 10/17/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190297231
Principal investigator 1 Novartis Pharmaceuticals Corporation $38.19 10/03/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190297242
Principal investigator 1 Novartis Pharmaceuticals Corporation $492.48 09/29/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190294233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,747.28 09/24/2025 Non-covered Recipient Entity
OVERLOOK FOUNDATION
ATLANTIC LIPID LOWERING TREATMENT OPTIMIZATION PROGRAM (ALLTOP): A COMPREHENSIVE APPROACH TO ADDRESSING DYSLIPIDEMIA AND COMORBIDITIES AMONG HIGH-RISK PATIENTS No dispute reported 06/30/2026 1184241964
Principal investigator 1 Eli Lilly and Company $165.35 09/19/2025 Non-covered Recipient Entity
NEW YORK UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187884692
Principal investigator 1 Novartis Pharmaceuticals Corporation $60,328.48 05/27/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190294226
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,697.10 02/19/2025 Non-covered Recipient Entity
GORYEB CHILDRENS HOSPITAL AT MORRISTOWN MEMORIAL
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190303857
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,790.10 02/04/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190297073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,747.28 01/29/2025 Non-covered Recipient Entity
OVERLOOK FOUNDATION
ATLANTIC LIPID LOWERING TREATMENT OPTIMIZATION PROGRAM (ALLTOP): A COMPREHENSIVE APPROACH TO ADDRESSING DYSLIPIDEMIA AND COMORBIDITIES AMONG HIGH-RISK PATIENTS No dispute reported 06/30/2026 1184149810
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,401.57 01/28/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190297070
Principal investigator 1 Amgen Inc. $119,884.93 01/21/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246637884
Principal investigator 1 Eli Lilly and Company $4,145.10 01/20/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187873127
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,682.48 01/15/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190294219
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,220.53 01/15/2025 Covered Recipient Teaching Hospital
Overlook Medical Center
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190294223
Principal investigator 1 Eli Lilly and Company $241,033.00 01/07/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187874923
Principal investigator 1 Novartis Pharmaceuticals Corporation $79,242.86 01/07/2025 Covered Recipient Teaching Hospital
Morristown Medical Center
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190297065